Candel Therapeutics Inc. logo

Candel Therapeutics Inc. (CADL)

Market Closed
24 Jul, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
7. 00
+0.04
+0.57%
$
350.34M Market Cap
- P/E Ratio
0% Div Yield
954,145 Volume
-0.91 Eps
$ 6.96
Previous Close
Day Range
6.92 7.21
Year Range
3.79 14.6
Want to track CADL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 18 days
Candel Therapeutics advancing lead candidate targeting prostate cancer towards FDA submission

Candel Therapeutics advancing lead candidate targeting prostate cancer towards FDA submission

Candel Therapeutics Inc (NASDAQ:CADL) has provided a corporate update, highlighting anticipated milestones for this year building upon significant achievements in 2024.   Updated overall survival data from phase 2a trials of its lead candidate CAN-2409 in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) are expected in the first quarter of 2025.

Proactiveinvestors | 6 months ago
2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases

2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases

In the New Year, many small-cap biotech companies will be advancing promising clinical trials with innovative therapies aimed at addressing significant unmet medical needs. Key trials include those focused on cancer immunotherapies, treatments for neurological conditions like multiple sclerosis and Alzheimer's, as well as novel approaches to metabolic diseases and chronic pain.

Proactiveinvestors | 7 months ago
Candel Therapeutics rides high on promising Phase 3 data, funding boost

Candel Therapeutics rides high on promising Phase 3 data, funding boost

Candel Therapeutics Inc (NASDAQ:CADL) shares skyrocketed by nearly 43% on Thursday following a string of positive news surrounding the company's cancer drug pipeline. Last week the Needham, Massachusetts-based company released promising results from its Phase 3 clinical trial for CAN-2409, its experimental immunotherapy for localized prostate cancer.

Proactiveinvestors | 7 months ago
Candel Therapeutics raises $92M in public offering following prostate cancer trial success

Candel Therapeutics raises $92M in public offering following prostate cancer trial success

Candel Therapeutics Inc (NASDAQ:CADL) announced on Monday the completion of a public offering that raised approximately $92 million in gross proceeds. The offering included 12 million shares of common stock at $6 per share and pre-funded warrants for 3.3 million shares at $5.99 per warrant, allowing buyers to acquire shares at an exercise price of $0.01 each.

Proactiveinvestors | 7 months ago
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 150 points on Friday.

Benzinga | 7 months ago
Candel Therapeutics unveils $80M public offering

Candel Therapeutics unveils $80M public offering

Candel Therapeutics Inc (NASDAQ:CADL) has announced an $80 million underwritten public offering of its common stock and pre-funded warrants. The offering includes approximately 10 million shares of common stock at $6 per share and approximately 3.33 million pre-funded warrants priced at $5.99 each, representing the public offering price minus a $0.01 per share exercise cost.

Proactiveinvestors | 7 months ago
CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal

CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal

Candel stock rallies 68% on meeting the primary goal in a phase III study of CAN-2409 combo therapy compared to SOC radiation therapy for prostate cancer.

Zacks | 7 months ago
Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight

Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight

Candel's phase 3 trial for CAN-2409 in high-risk prostate cancer met its primary endpoint, showing a 14.5% improvement in disease-free survival over placebo. Financially, CADL holds $16.6 million in cash, facing a likely equity raise soon due to high operational expenses and limited cash runway. Despite a phase 2b trial setback in lower-risk prostate cancer, the phase 3 success supports a potential FDA submission by mid-2025.

Seekingalpha | 7 months ago
Biotech Stock Hits 3-Year Highs on Trial Results

Biotech Stock Hits 3-Year Highs on Trial Results

Candel Therapeutics Inc (NASDAQ:CADL) is soaring today, up 164% at $12.17 at last glance and earlier hitting a three-year high of $14.60, after the biotech company's prostate cancer immunotherapy treatment, CAN-2409, met its goal in a late-stage study.

Schaeffersresearch | 7 months ago
Candel Therapeutics Stock Surges Over 100% - Here's Why

Candel Therapeutics Stock Surges Over 100% - Here's Why

On Wednesday, Candel Therapeutics, Inc. CADL announced results from a phase 3 trial of CAN-2409 viral immunotherapy in intermediate-to-high-risk, localized prostate cancer patients.

Benzinga | 7 months ago
Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer Drug

Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer Drug

Shares of Candel Therapeutics skyrocketed Wednesday after the biotech company's prostate cancer treatment succeeded in a Phase 3 study. The post Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer Drug appeared first on Investor's Business Daily.

Investors | 7 months ago
Candel Therapeutics reports positive Phase 3 results for CAN-2409 in localized prostate cancer

Candel Therapeutics reports positive Phase 3 results for CAN-2409 in localized prostate cancer

Candel Therapeutics Inc (NASDAQ:CADL) announced that its experimental immunotherapy, CAN-2409, met its main goal in a Phase 3 trial, significantly improving disease-free survival in patients with localized prostate cancer. The trial showed a 14.5% improvement in disease-free survival (DFS) at 54 months for the CAN-2409 group compared to the control arm and significantly reduced recurrence risk while improving prostate cancer-free survival.

Proactiveinvestors | 7 months ago
Loading...
Load More